FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar. This includes but is not limited to persons residing in Mississippi.

EFFECT OF ACTOS

Actos® is a pioglitazone drug used to treat type 2 diabetes. Pioglitazone is an insulin sensitizer that works by making the tissues more sensitive to the effects of insulin. Bladder Cancer is a potential side effect of Actos®. Another of the potential side effects of the drug Actos is sinusitis. Sinusitis is the inflammation of the sinus cavities surrounding the nose and connected to it by tubes.

Bladder Cancer

Another common yet dangerous potential side effect that may be related to ingestion of Actos is bladder cancer. Bladder cancer is the second most common form of urinary tract cancer after prostrate cancer. The urinary tract consists of two kidneys, two tubes called ureters that run down from the kidneys to enter the back of the base of the bladder, the expansible muscular bladder itself with its control sphincter and a single outlet tube, the urethra that carries urine from the bladder to the exterior. The kidney and bladder are the major organs of the urinary tract, the system that removes body waste through the production and excretion of urine. In the process of filtering waste products from the blood, the kidney produces urine, which is then stored in the reservoir of the bladder. Bladder cancer can affect the entire urinary system.

Sinusitis

Patients who have consumed Actos for treating diabetes have complained of sinusitis. The sinuses are small cavities in the bones of the face. They contain air thus contributing to the skull’s lightness. The sinus cavities are linked with the nose and the upper throat and are therefore vulnerable to the spread of infection from these areas. Sinusitis can be acute or chronic. Each has different symptoms.

Headache associated with sinusitis is caused by infection and inflammation. The pain of sinusitis is usually dull and achy, and if there is a bacterial infection, the pain may be accompanied by fever and may last until antibiotics are taken.

Acute sinusitis gives rise to pain and sometimes redness and swelling over the sinus. The nose is blocked on the affected side but there may be very little discharge. The senses of smell and taste are usually reduced. Acute sinusitis is defined as a sinus infection that lasts less than 3 weeks. Sinusitis that has continued for 3 months or more is considered chronic.

Chronic sinusitis produces nasal discharge, low grade pain, a blocked nose and cough. Sometimes the infection of one of the frontal sinuses spreads around the eye causing double vision, swelling of the eyelids or even an abscess behind the eyeball which pushes it outward. Meningitis or a brain abscess may also develop.

Chronic sinusitis appears to result from episodes of prolonged, repeated, or inadequately treated acute sinusitis. Chronic sinusitis generally presents with dull ache or pressure across the midface, which patients characterize as a headache. The headache may be worse in the morning and with head movement. In addition, patients may also complain of nasal congestion and thick pharyngeal secretions, blocked or popping ears, dental pain, chronic cough, mild facial swelling, and eye pain

Sinusitis can be difficult to treat once a chronic condition has become established and each ensuing infection can cause a more stubborn chronic infection than the previous infection. Unduly vigorous nose blowing should be avoided; this can force infected material into the sinuses. Nose drops and sprays should not be used for more than a week at a time because they can create further problems.  Acute sinusitis often clears up with antibiotics and nose drops. Chronic sinusitis however may last a long time.

We stand ready to discuss Actos and bladder cancer with you.

MORE ABOUT ACTOS

Actos is a drug used to treat Type 2 diabetes. While the drug is effective, it does have certain side effects, which can include the following:

Pharyngitis

One of the common side effects of Actos is Pharyngitis. Pharyngitis is the inflammation of the pharynx. It is experienced as a sore throat. Pharyngitis can appear suddenly (acute) or it can persist over several months or even years (chronic).

The pharynx provides a vital link between the nose, mouth and the voice box. In doing so it plays a major role in the essential tasks of breathing, eating and speaking. The pharynx is deep lined with muscles and is shaped very roughly like an inverted cone. It extends for about 5 inches behind the arch at the back of the mouth to where it joins the gullet.

Myalgias

Another common side effect of Actos is myalgisa. Myalgisa refers to aching in the muscles. It is common in the upper or lower back and neck areas. It is usually present on both the left and right sides and present as a dull throbbing discomfort.

Sinusitis

Yet another commons side effect of Actos is sinusitis. Sinusitis is inflammation of the mucosal lining of the paranasal sinuses, which leads to stasis, obstruction, and subsequent infection. The sinuses are air-filled bony cavities that produce and drain up to 2 pints of mucus every day. Self-cleaning occurs by movement of the mucus, propelled by cilia, through the ostia, which are located behind the turbinates. Acute sinusitis is a bacterial infection of one or more paranasal sinuses, which occurs when the normal drainage is impaired because of blockage of one or more ostia.

Hypoglycemia 

Some patients who were prescribed Actos for treatment of type 2 diabetes have reported hypoglycemia. Hypoglycemia is the condition in which the level of glucose falls below normal levels affecting the individual’s ability to process information, including interruption in short-term memory, decrements in motor control (weakness), and other autonomic and adrenergic symptoms (e.g., trembling, difficulty concentrating, tiredness, headache, sweating, dry mouth, and hunger).

Serious Complications

Besides the general side effects, Acots can also cause serious medical problems such as bladder cancer and congestive heart failure.

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar. This includes but is not limited to persons residing in Arkansas.

EFFECT OF ACTOS

Actos® is a pioglitazone drug used to treat type 2 diabetes. Pioglitazone is an insulin sensitizer that works by making the tissues more sensitive to the effects of insulin. Bladder Cancer is a potential side effect of Actos®. Another of the potential side effects of the drug Actos is sinusitis. Sinusitis is the inflammation of the sinus cavities surrounding the nose and connected to it by tubes.

Bladder Cancer

Another common yet dangerous potential side effect that may be related to ingestion of Actos is bladder cancer. Bladder cancer is the second most common form of urinary tract cancer after prostrate cancer. The urinary tract consists of two kidneys, two tubes called ureters that run down from the kidneys to enter the back of the base of the bladder, the expansible muscular bladder itself with its control sphincter and a single outlet tube, the urethra that carries urine from the bladder to the exterior. The kidney and bladder are the major organs of the urinary tract, the system that removes body waste through the production and excretion of urine. In the process of filtering waste products from the blood, the kidney produces urine, which is then stored in the reservoir of the bladder. Bladder cancer can affect the entire urinary system.

Sinuses

The sinuses are a network of hollow spaces behind the nose. They occupy most of the front of the head and drain upper airway mucus as well as act as a generalized cleanser of facial and nasal tissue. These caves are connected by narrow holes or orifices. If these orifices become blocked, as happens all too often, the caves behind them also become clogged and inflamed. The chronic inflammation that occurs in these caves, or sinuses — sinusitis — is one of the more common chronic debilitating diseases, and it is often associated with asthma and hay fever.

Individuals with sinusitis complain of a heaviness often a bogginess, behind the nose and below the eyes. The bogginess may become so severe that a characteristic sinus headache results. If the sinus becomes infected, there may be a fever accompanied by a purulent (pus) discharge from the nose. The headache and the pain of sinusitis produce acute discomfort.

Sinusitis can cause localized dull headaches in the forehead, behind and between the eyes or in the cheeks. The pain can radiate to the temples or to the top or back of the head and can become worse when bending forward. Thick yellowish-greenish nasal drainage occurs. Sometimes sinusitis is accompanied by teeth pain.

Acute sinusitis gives rise to pain and sometimes redness and swelling over the sinus. The person may have a severe localized headache depending on which sinus is affected. Frontal sinusitis produces pain above the eyes. In maxillary sinusitis, the paid is in the cheeks which is often throbbing and is made worse by bending down or moving the head.

Jaundice

Another lesser known but potential side effect of Actos is Jaundice. It does not medically qualify as a rash; this condition manifests itself in a yellowish cast to the skin. Jaundice requires a thorough evaluation in order to be appropriately treated. When gallstones block the drainage of the liver into the intestine, surgical removal of the stones restores the liver’s access, thereby causing the jaundice to resolve.

We stand ready to discuss Actos and bladder cancer with you.

MORE ABOUT ACTOS

Actos is a drug used to treat Type 2 diabetes. While the drug is effective, it does have certain side effects, which can include the following:

Pharyngitis

One of the common side effects of Actos is Pharyngitis. Pharyngitis is the inflammation of the pharynx. It is experienced as a sore throat. Pharyngitis can appear suddenly (acute) or it can persist over several months or even years (chronic).

The pharynx provides a vital link between the nose, mouth and the voice box. In doing so it plays a major role in the essential tasks of breathing, eating and speaking. The pharynx is deep lined with muscles and is shaped very roughly like an inverted cone. It extends for about 5 inches behind the arch at the back of the mouth to where it joins the gullet.

Myalgias

Another common side effect of Actos is myalgisa. Myalgisa refers to aching in the muscles. It is common in the upper or lower back and neck areas. It is usually present on both the left and right sides and present as a dull throbbing discomfort.

Sinusitis

Yet another commons side effect of Actos is sinusitis. Sinusitis is inflammation of the mucosal lining of the paranasal sinuses, which leads to stasis, obstruction, and subsequent infection. The sinuses are air-filled bony cavities that produce and drain up to 2 pints of mucus every day. Self-cleaning occurs by movement of the mucus, propelled by cilia, through the ostia, which are located behind the turbinates. Acute sinusitis is a bacterial infection of one or more paranasal sinuses, which occurs when the normal drainage is impaired because of blockage of one or more ostia.

Hypoglycemia 

Some patients who were prescribed Actos for treatment of type 2 diabetes have reported hypoglycemia. Hypoglycemia is the condition in which the level of glucose falls below normal levels affecting the individual’s ability to process information, including interruption in short-term memory, decrements in motor control (weakness), and other autonomic and adrenergic symptoms (e.g., trembling, difficulty concentrating, tiredness, headache, sweating, dry mouth, and hunger).

Serious Complications

Besides the general side effects, Acots can also cause serious medical problems such as bladder cancer and congestive heart failure.

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar. This includes but is not limited to persons residing in Tennessee.

EFFECT OF ACTOS

Actos® is a pioglitazone drug used to treat type 2 diabetes. Pioglitazone is an insulin sensitizer that works by making the tissues more sensitive to the effects of insulin. Bladder Cancer is a potential side effect of Actos®. Upper respiratory infections are another potential side effect of Actos. Upper respiratory infections include the common cold, pharyngitis, and otitis media.

Pharyngitis

The pharynx is composed of three sections — the nasal pharynx (area behind the nose), the oral pharynx (area behind the mouth), and the laryngeal pharynx (area behind the larynx). Pharyngitis is an inflammatory illness of the mucous membranes and underlying structures of the throat. Pharyngitis can be divided into two categories: with nasal symptoms (nasopharyngitis) and without (pharyngitis or tonsillopharyngitis).

While sore throat is always present with pharyngitis, it does not guarantee that pharyngitis is present. Children with colds without evidence of pharyngeal inflammation may report sore throats. In addition to sore throat, pharyngitis is often accompanied by fever, headache, nausea, vomiting, anorexia, some degree of lessened activity, and sometimes abdomina pain. Cervical lymph nodes may be enlarged and tender.

Otitis media

Otitis media is the nfection or inflammation of the middle ear space (between the eardrum and the inner ear). Otitis media is usually further specified as the following:

• Acute otitis media—Infected fluid behind the eardrum, usually with a rapid onset of fever and pain.
• Chronic otitis media—Infected fluid behind the eardrum, persisting despite treatment with antibiotics, and sometimes associated with drainage from a perforation of the eardrum.
• Otitis media with effusion (OME)—Fluid behind the eardrum which is not infected.
• Chronic OME—Fluid persisting in the middle ear for longer than 6 to 8 weeks

Bladder Cancer

Another common yet dangerous potential side effect that may be related to ingestion of Actos is bladder cancer. Bladder cancer is the second most common form of urinary tract cancer after prostrate cancer. The urinary tract consists of two kidneys, two tubes called ureters that run down from the kidneys to enter the back of the base of the bladder, the expansible muscular bladder itself with its control sphincter and a single outlet tube, the urethra that carries urine from the bladder to the exterior. The kidney and bladder are the major organs of the urinary tract, the system that removes body waste through the production and excretion of urine. In the process of filtering waste products from the blood, the kidney produces urine, which is then stored in the reservoir of the bladder. Bladder cancer can affect the entire urinary system.

We stand ready to discuss Actos and bladder cancer with you.

MORE ABOUT ACTOS

Actos is a drug used to treat Type 2 diabetes. While the drug is effective, it does have certain side effects, which can include the following:

Pharyngitis

One of the common side effects of Actos is Pharyngitis. Pharyngitis is the inflammation of the pharynx. It is experienced as a sore throat. Pharyngitis can appear suddenly (acute) or it can persist over several months or even years (chronic).

The pharynx provides a vital link between the nose, mouth and the voice box. In doing so it plays a major role in the essential tasks of breathing, eating and speaking. The pharynx is deep lined with muscles and is shaped very roughly like an inverted cone. It extends for about 5 inches behind the arch at the back of the mouth to where it joins the gullet.

Myalgias

Another common side effect of Actos is myalgisa. Myalgisa refers to aching in the muscles. It is common in the upper or lower back and neck areas. It is usually present on both the left and right sides and present as a dull throbbing discomfort.

Sinusitis

Yet another commons side effect of Actos is sinusitis. Sinusitis is inflammation of the mucosal lining of the paranasal sinuses, which leads to stasis, obstruction, and subsequent infection. The sinuses are air-filled bony cavities that produce and drain up to 2 pints of mucus every day. Self-cleaning occurs by movement of the mucus, propelled by cilia, through the ostia, which are located behind the turbinates. Acute sinusitis is a bacterial infection of one or more paranasal sinuses, which occurs when the normal drainage is impaired because of blockage of one or more ostia.

Hypoglycemia 

Some patients who were prescribed Actos for treatment of type 2 diabetes have reported hypoglycemia. Hypoglycemia is the condition in which the level of glucose falls below normal levels affecting the individual’s ability to process information, including interruption in short-term memory, decrements in motor control (weakness), and other autonomic and adrenergic symptoms (e.g., trembling, difficulty concentrating, tiredness, headache, sweating, dry mouth, and hunger).

Serious Complications

Besides the general side effects, Acots can also cause serious medical problems such as bladder cancer and congestive heart failure.

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar.

EFFECT OF ACTOS

Actos® is a pioglitazone drug used to treat type 2 diabetes. Pioglitazone is an insulin sensitizer that works by making the tissues more sensitive to the effects of insulin. Bladder Cancer is a potential side effect of Actos®.

Bladder cancer is a painful and potentially fatal disease. Depending on when the disease is diagnosed, patients may face years of invasive treatments such as: chemotherapy, radiation treatment, surgery or immunotherapy. If you file an Actos lawsuit and win, damages can be recovered for all related medical care, pain and even death.

The FDA recently warned about Actos. The FDA’s warning is based on a planned five-year interim data analysis of an ongoing 10-year study.  A previous study in France concluded that long-term use of Actos and higher cumulative doses significantly increased the risk of bladder cancer. Germany no longer allows new patients to use the drug.

Our team of attorneys represent clients with bladder cancer who have taken Actos. Please note that users should not discontinue taking Actos simply because it may cause an increased risk of bladder cancer. Users should instead visit with their doctors to discuss concerns.

In response to the FDA safety announcement, a joint statement was released from the Endocrine Society, American Association of Clinical Endocrinologists and the American Diabetes association. They urged patients who are currently taking Actos, or any combination medication that includes the drug, to continue taking all currently prescribed medications unless instructed otherwise by their healthcare provider.

They stated, “Stopping diabetes medications can result in higher levels of blood glucose that may cause serious short-term health problems and could increase the risk of diabetes-related complications in the long term.”

We stand ready to discuss Actos and bladder cancer with you.

MORE ABOUT ACTOS

Actos is a drug used to treat Type 2 diabetes. While the drug is effective, it does have certain side effects, which can include the following:

Pharyngitis

One of the common side effects of Actos is Pharyngitis. Pharyngitis is the inflammation of the pharynx. It is experienced as a sore throat. Pharyngitis can appear suddenly (acute) or it can persist over several months or even years (chronic).

The pharynx provides a vital link between the nose, mouth and the voice box. In doing so it plays a major role in the essential tasks of breathing, eating and speaking. The pharynx is deep lined with muscles and is shaped very roughly like an inverted cone. It extends for about 5 inches behind the arch at the back of the mouth to where it joins the gullet.

Myalgias

Another common side effect of Actos is myalgisa. Myalgisa refers to aching in the muscles. It is common in the upper or lower back and neck areas. It is usually present on both the left and right sides and present as a dull throbbing discomfort.

Sinusitis

Yet another commons side effect of Actos is sinusitis. Sinusitis is inflammation of the mucosal lining of the paranasal sinuses, which leads to stasis, obstruction, and subsequent infection. The sinuses are air-filled bony cavities that produce and drain up to 2 pints of mucus every day. Self-cleaning occurs by movement of the mucus, propelled by cilia, through the ostia, which are located behind the turbinates. Acute sinusitis is a bacterial infection of one or more paranasal sinuses, which occurs when the normal drainage is impaired because of blockage of one or more ostia.

Hypoglycemia 

Some patients who were prescribed Actos for treatment of type 2 diabetes have reported hypoglycemia. Hypoglycemia is the condition in which the level of glucose falls below normal levels affecting the individual’s ability to process information, including interruption in short-term memory, decrements in motor control (weakness), and other autonomic and adrenergic symptoms (e.g., trembling, difficulty concentrating, tiredness, headache, sweating, dry mouth, and hunger).

Serious Complications

Besides the general side effects, Acots can also cause serious medical problems such as bladder cancer and congestive heart failure.

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FREE CASE EVALUATION: 1-800-632-1404

Tens of thousands of women receive a transvaginal mesh (TVM) device each and every year from numerous suppliers: American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson.  Thousands of women have been injured through no fault of their own, including vaginal erosion, pain, urinary problems, bleeding, infection and more. Our attorneys are representing women in all fifty states and Canada who have been injured.  For a free case evaluation, call 1-800-632-1404.

We are honored to have two women on staff ready and willing to discuss the facts of your case with you as often as needed.

Johnson & Johnson: One of the Worst in 2011

Website 24/7 Wall Street listed its Ten Most Hated Companies in 2011, and on the list was Ethicon’s Johnson & Johnson. As many of you reading this will know, claims have been filed as a result of Ethicon’s transvaginal mesh POP device. The precise quote from the website is:

Johnson & Johnson (NYSE: JNJ) has experienced a series of product recalls and problems that began with Motrin and Tylenol for children. According to AP, these recalls were among “more than two dozen that J&J has issued since September 2009, for products ranging from adult and children’s nonprescription Tylenol, Motrin, Benadryl and other medicines to prescription drugs for HIV and seizures, defective hip implants that caused severe pain and contact lenses that irritated the eyes.” The parents of a two-year-old who was treated with one of the tainted batches of Children’s Tylenol recently sued the company for the wrongful death of their child. In March 2011, the FDA took over three Tylenol plants owned by Johnson & Johnson. The recalls are beginning to hurt the company. Third-quarter 2011 sales of over-the-counter drugs fell 24% from the previous year. According to Bloomberg, company executives attributed the significant loss of market share to quality issues that kept products off shelves. The long series of problems has ruined what was once a sterling reputation. Since the disclosures mounted two years ago, Johnson & Johnson shares are flat while the DJIA is up 17%, over the past year.

Our team of attorneys is reviewing case evaluations for women across the country who have received TVM and TVT products from manufactures such as C.R. Bard, Avaulta, Boston Scientific, and Johnson & Johnson’s Ethicon.

If you need help from a transvaginal mesh device injury, call us today for help.

The Problem

In 2008, the FDA first released concerns about the safety of transvaginal placement of mesh. From 2008 to 2010, the FDA received three to five times as many adverse reports associated with mesh used for pelvic organ prolapse repair than what agency received from 2005 to 2007 (nearly 1,000 reports of adverse events were received from 2005-2007).

Many of these patients complain because of erosion or contraction of the mesh material (which has been described as being of a similar material as Rubbermaid storage containers).  The erosion leads to bleeding, severe pelvic pain, painful (or impossible) sexual performance and a recurrence of urinary problems.

In July 2011, the Food and Drug Administration (FDA) issued an update related to what it called ‘serious complications’ related to the use of vaginal mesh for treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI).  It is now known that complications linked to transvaginal placement of surgical mesh in SUI and POP patients are not rare and can require multiple surgeries to correct problems related to the use of surgical mesh. In fact, the FDA now says that additional surgeries may actually not be able to repair damage caused by implantation of the mesh.

In other words, the side effects of the mesh placement may be permanent.  These complications from transvaginal placement of surgical mesh include:

• -Erosion of the implanted mesh
• -Infection and/or bleeding
• -Pain, including pain during sexual intercourse
• -Problems with organs near the implantation site

Helping You

You may have experienced mesh erosion, bleeding, urinary infections, vaginal scarring, pain during sexual intercourse, failure to conduct sexual intercourse and more. A physician may have tried to remove the mesh and been unable to do so. You may be in excruciating pain, and need help. We are offering free case evaluations to the general public across the United States and Canada. Manufacturers we consider include American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson.

If you received a transvaginal mesh / sling and have been injured, you may be entitled to monetary compensation. Problems include pain, inability to have intercourse,bleeding, mesh growth into the body, mesh erosion, and more. Problems could be irreversible. Please fill out the form to the right or call us so that we can provide you with forms to evaluate your potential case immediately.

We are accepting case evaluations nationwide and in Canada, as well.  Please do not hesitate or delay in contacating TVM / TVT Sling and transvaginal mesh attorneys :

CALL: 1-800-632-1404

EMAIL: clicking here

FILL OUT THIS FORM FOR A FREE CONSULTATION AND CASE EVALUATION:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar.

WHAT IS BLADDER CANCER?

Actos® is a pioglitazone drug used to treat type 2 diabetes. Pioglitazone is an insulin sensitizer that works by making the tissues more sensitive to the effects of insulin. Bladder Cancer is a potential side effect of Actos®.

Bladder cancer is a painful and potentially fatal disease. Depending on when the disease is diagnosed, patients may face years of invasive treatments such as: chemotherapy, radiation treatment, surgery or immunotherapy. If you file an Actos lawsuit and win, damages can be recovered for all related medical care, pain and even death.

Symptoms of bladder cancer can include:

1. Abdominal pain
2. Blood in the urine
3. Bone pain or tenderness
4. Fatigue
5. Painful urination
6. Urinary frequency
7. Urinary urgency
8. Urine leakage (incontinence)
9. Weight loss

MORE ABOUT ACTOS

Actos is a drug used to treat Type 2 diabetes. While the drug is effective, it does have certain side effects, which can include the following:

Pharyngitis

One of the common side effects of Actos is Pharyngitis. Pharyngitis is the inflammation of the pharynx. It is experienced as a sore throat. Pharyngitis can appear suddenly (acute) or it can persist over several months or even years (chronic).

The pharynx provides a vital link between the nose, mouth and the voice box. In doing so it plays a major role in the essential tasks of breathing, eating and speaking. The pharynx is deep lined with muscles and is shaped very roughly like an inverted cone. It extends for about 5 inches behind the arch at the back of the mouth to where it joins the gullet.

Myalgias

Another common side effect of Actos is myalgisa. Myalgisa refers to aching in the muscles. It is common in the upper or lower back and neck areas. It is usually present on both the left and right sides and present as a dull throbbing discomfort.

Sinusitis

Yet another commons side effect of Actos is sinusitis. Sinusitis is inflammation of the mucosal lining of the paranasal sinuses, which leads to stasis, obstruction, and subsequent infection. The sinuses are air-filled bony cavities that produce and drain up to 2 pints of mucus every day. Self-cleaning occurs by movement of the mucus, propelled by cilia, through the ostia, which are located behind the turbinates. Acute sinusitis is a bacterial infection of one or more paranasal sinuses, which occurs when the normal drainage is impaired because of blockage of one or more ostia.

Hypoglycemia 

Some patients who were prescribed Actos for treatment of type 2 diabetes have reported hypoglycemia. Hypoglycemia is the condition in which the level of glucose falls below normal levels affecting the individual’s ability to process information, including interruption in short-term memory, decrements in motor control (weakness), and other autonomic and adrenergic symptoms (e.g., trembling, difficulty concentrating, tiredness, headache, sweating, dry mouth, and hunger).

Serious Complications

Besides the general side effects, Acots can also cause serious medical problems such as bladder cancer and congestive heart failure.

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FREE CASE EVALUATION: 1-800-632-1404

Tens of thousands of women receive a transvaginal mesh (TVM) device each and every year from numerous suppliers: American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson.  Thousands of women have been injured through no fault of their own, including vaginal erosion, pain, urinary problems, bleeding, infection and more. Our attorneys are representing women in all fifty states and Canada who have been injured.  For a free case evaluation, call 1-800-632-1404.

We are honored to have two women on staff ready and willing to discuss the facts of your case with you as often as needed.

FDA Issues Mandate

The FDA issued a mandate this week requiring the manufacturers of transvaginal mesh (TVM) products, including American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson, to study the risks and complications of device usage. As a service to the public at large, these are four separate news sources reporting on this pandemic that is affecting thousands of women.

Increased reports of complications have prompted the US Food and Drug Administration (FDA) to order new postmarket surveillance (522) studies of surgical mesh implants used to treat pelvic organ prolapse and stress urinary incontinence. The FDA is also considering reclassifying urogynecologic surgical mesh used for transvaginal repair of pelvic organ prolapse from Class II to Class III, a higher-risk category that would require clinical trials before approval.

Under the new FDA order, manufacturers will be required to submit study plans to the FDA that address specific safety and effectiveness concerns related to surgical mesh devices for prolapse and single-incision mini-sling devices for stress incontinence. Data from the studies will enable the agency to better understand the safety and effectiveness profiles of these devices.

The FDA said it continues to assess the safety and effectiveness of urogynecologic surgical mesh devices through the following additional actions:

1. Review and analysis of published literature, Medical Device Reports submitted to the agency, and post-approval study reports
2. Epidemiologic research on safety and effectiveness of surgical mesh
3. Collaborations with professional societies and other stakeholders to fully understand the postmarket performance of urogynecologic surgical mesh devices, as well as the occurrence of and signs and symptoms associated with specific adverse events
4. Collecting and reviewing all available information about currently marketed urogynecologic surgical mesh devices.

The following is required

• - 88 orders for postmarket surveillance studies were issued to 33 manufacturers of urogynecologic surgical mesh for pelvic organ prolapse (POP);
• - 11 orders for postmarket surveillance studies were issued to seven manufacturers of single-incision mini-slings for stress urinary incontinence (SUI); and
• - All manufacturers will be required to submit study plans to the FDA that address specific safety and effectiveness concerns related to surgical mesh for POP and single-incision mini-slings for SUI devices.

Our team of attorneys is reviewing case evaluations for women across the country who have received TVM and TVT products from manufactures such as C.R. Bard, Avaulta, Boston Scientific, and Johnson & Johnson’s Ethicon.

If you need help from a transvaginal mesh device injury, call us today for help.

The Problem

In 2008, the FDA first released concerns about the safety of transvaginal placement of mesh. From 2008 to 2010, the FDA received three to five times as many adverse reports associated with mesh used for pelvic organ prolapse repair than what agency received from 2005 to 2007 (nearly 1,000 reports of adverse events were received from 2005-2007).

Many of these patients complain because of erosion or contraction of the mesh material (which has been described as being of a similar material as Rubbermaid storage containers).  The erosion leads to bleeding, severe pelvic pain, painful (or impossible) sexual performance and a recurrence of urinary problems.

In July 2011, the Food and Drug Administration (FDA) issued an update related to what it called ‘serious complications’ related to the use of vaginal mesh for treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI).  It is now known that complications linked to transvaginal placement of surgical mesh in SUI and POP patients are not rare and can require multiple surgeries to correct problems related to the use of surgical mesh. In fact, the FDA now says that additional surgeries may actually not be able to repair damage caused by implantation of the mesh.

In other words, the side effects of the mesh placement may be permanent.  These complications from transvaginal placement of surgical mesh include:

• -Erosion of the implanted mesh
• -Infection and/or bleeding
• -Pain, including pain during sexual intercourse
• -Problems with organs near the implantation site

Helping You

You may have experienced mesh erosion, bleeding, urinary infections, vaginal scarring, pain during sexual intercourse, failure to conduct sexual intercourse and more. A physician may have tried to remove the mesh and been unable to do so. You may be in excruciating pain, and need help. We are offering free case evaluations to the general public across the United States and Canada. Manufacturers we consider include American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson.

If you received a transvaginal mesh / sling and have been injured, you may be entitled to monetary compensation. Problems include pain, inability to have intercourse,bleeding, mesh growth into the body, mesh erosion, and more. Problems could be irreversible. Please fill out the form to the right or call us so that we can provide you with forms to evaluate your potential case immediately.

We are accepting case evaluations nationwide and in Canada, as well.  Please do not hesitate or delay in contacating TVM / TVT Sling and transvaginal mesh attorneys :

CALL: 1-800-632-1404

EMAIL: clicking here

FILL OUT THIS FORM FOR A FREE CONSULTATION AND CASE EVALUATION:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar.

WHAT IS BLADDER CANCER?

Actos® is a pioglitazone drug used to treat type 2 diabetes. Pioglitazone is an insulin sensitizer that works by making the tissues more sensitive to the effects of insulin. Bladder Cancer is a potential side effect of Actos®.

Bladder cancer is a painful and potentially fatal disease. Depending on when the disease is diagnosed, patients may face years of invasive treatments such as: chemotherapy, radiation treatment, surgery or immunotherapy. If you file an Actos lawsuit and win, damages can be recovered for all related medical care, pain and even death.

Symptoms of bladder cancer can include:

1. Abdominal pain
2. Blood in the urine
3. Bone pain or tenderness
4. Fatigue
5. Painful urination
6. Urinary frequency
7. Urinary urgency
8. Urine leakage (incontinence)
9. Weight loss

The prognosis for patients suffering from bladder cancer can vary depending on what stage the bladder cancer was when discovered. For example, a patient with initial stage bladder cancer should hopefully respond well to the treatment. In the higher (and later) stages of cancer, bladder cancer may be curable with the proper treatment and/or surgery. The cure rates for patients with state III bladder cancer the cure rate is less than 50% and those with Stage IV bladder cancer are rarely cured.

Unfortunately for patients, bladder cancer may also spread into the neighboring organs, and bladder cancer can travel through the pelvic lymph nodes and spread to the liver, lungs, and bones. By speaking with our Actos lawsuit attorneys, you and your family may get the justice and compensation you need and deserve.

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar.

ACTOS AND PRODUCT LIABILITY

Actos® is a pioglitazone drug used to treat type 2 diabetes. Pioglitazone is an insulin sensitizer that works by making the tissues more sensitive to the effects of insulin. Bladder Cancer and Congestive Heart Failure are two potential side effects of Actos®.

Prescription drugs may not be sold in the United States unless they are first approved by the FDA.  A manufacturer seeking approval to market a new drug – often called the “referenced listed drug” or “RLD” – must submit a New Drug Application (“NDA”) to the FDA, with proof that the drug is safe and effective and the proposed label is accurate and adequate.  See, e.g., 21 U.S.C. § 355 (b)(1), (d). 

A manufacturer of a generic drug, which is designed to be a copy of a previously-approved RLD, can gain expedited FDA approval by submitting an Abbreviated New Drug Application (“ANDA”) demonstrating that its generic drug is “bioequivalent” to the RLD and its proposed safety and efficacy labeling is “the same as the labeling approved for the [brand-name] drug.”  See Pliva v. Mensing, 131 S. Ct. 2567, 2574 (2011) (quoting 21 U.S.C. § 355(j)(2)(A)(v)).  As addressed below, because the products are bioequivalent, doctors and pharmacists frequently rely on representations made by the RLD-holder in prescribing and dispensing generic versions of a drug.

Because knowledge about a drug’s benefits and risks grows over time, especially after a drug has begun to be marketed, the FDA has procedures by which a manufacturer can change an approved application or labeling.  In fact, FDA regulations require that the labeling “be revised to include a warning as soon as there is reasonable evidence of an association of a serious hazard with a drug; a causal relationship need not have been proved.”  21 C.F.R. § 201.80(e). 
Most changes to a drug’s labeling are requested through a “Prior Approval Supplement,” which, as the name implies, requires FDA approval before the change may be implemented.  See 21 C.F.R. § 314.70(b).  If the change is to “add or strengthen a contraindication, warning, precaution, or adverse reaction,” however, it may be done through a “Changes Being Effected” (“CBE”) supplement, which allows the change to be implemented before the FDA has acted on the application.  See 21 C.F.R. § 314.70(c).  While brand and generic manufacturers may use both types of supplements, see 21 C.F.R. § 314.97, generic manufacturers are more limited in what they can do, because they are always subject to the requirement that their labels be the same as that of the RLD.  Mensing, 131 S. Ct. at 2575.

Drug companies may also communicate information about their drugs to doctors and pharmacies through other means.  For example, manufacturers of brand-name drugs typically pay to publish their drugs’ labeling information in the Physician’s Desk Reference (“PDR”), which is provided for free to doctors and pharmacists across the nation, and is the primary way in which they receive information about the efficacy of, and risks associated with, prescription drugs.  See Conte v. Wyeth, Inc., 168 Cal. App. 4th 89, 98 n.4 (Cal. Ct. App. 2008); See Allen Rostron, Prescription for Fairness:  A New Approach to Tort Liability of Brand-Name and Generic Drug Manufacturers, 60 Duke L.J. 1123, 1133 (2011).  Drug products are listed by both their brand and generic names, id., just as the brand-name product label refers to the generic name of the drug throughout.  See 21 C.F.R. § 201.57(a)(2).  Brand manufacturers also sometimes communicate information through the use of “Dear Health Care Professional” (“DHCP”) letters.

There are no regulations prohibiting generic drug companies from communicating in these ways, but they rarely if ever choose to do so, and instead rely on the brand manufacturers to communicate information about the drugs.  Even if generic manufacturers would choose to use those methods of communications, the FDA considers them to constitute “labeling,” so they also “must be consistent with and not contrary to [the RLD’s] approved . . . labeling.”  See 21 C.F.R. § 201.100(d)(1).

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments

FREE CASE EVALUATION: 1-800-632-1404

Tens of thousands of women receive a transvaginal mesh (TVM) device each and every year from numerous suppliers: American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson.  Thousands of women have been injured through no fault of their own, including vaginal erosion, pain, urinary problems, bleeding, infection and more. Our attorneys are representing women in all fifty states and Canada who have been injured.  For a free case evaluation, call 1-800-632-1404.

We are honored to have two women on staff ready and willing to discuss the facts of your case with you as often as needed.

FDA Issues Mandate

The FDA issued a mandate this week requiring the manufacturers of transvaginal mesh (TVM) products, including American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson, to study the risks and complications of device usage. As a service to the public at large, these are four separate news sources reporting on this pandemic that is affecting thousands of women.

Increased reports of complications have prompted the US Food and Drug Administration (FDA) to order new postmarket surveillance (522) studies of surgical mesh implants used to treat pelvic organ prolapse and stress urinary incontinence.

The FDA is also considering reclassifying urogynecologic surgical mesh used for transvaginal repair of pelvic organ prolapse from Class II to Class III, a higher-risk category that would require clinical trials before approval. 

Under the new FDA order, manufacturers will be required to submit study plans to the FDA that address specific safety and effectiveness concerns related to surgical mesh devices for prolapse and single-incision mini-sling devices for stress incontinence. Data from the studies will enable the agency to better understand the safety and effectiveness profiles of these devices.

The FDA said it continues to assess the safety and effectiveness of urogynecologic surgical mesh devices through the following additional actions:

1. Review and analysis of published literature, Medical Device Reports submitted to the agency, and post-approval study reports
2. Epidemiologic research on safety and effectiveness of surgical mesh
3. Collaborations with professional societies and other stakeholders to fully understand the postmarket performance of urogynecologic surgical mesh devices, as well as the occurrence of and signs and symptoms associated with specific adverse events
4. Collecting and reviewing all available information about currently marketed urogynecologic surgical mesh devices.

This issue has been reported by Modern Medicine.

To date, the FDA has not released these mandates, but as soon as they are issued, you can be assured this website will post for the world to see.

Our team of attorneys is reviewing case evaluations for women across the country who have received TVM and TVT products from manufactures such as C.R. Bard, Avaulta, Boston Scientific, and Johnson & Johnson’s Ethicon.

If you need help from a transvaginal mesh device injury, call us today for help.

The Problem

In 2008, the FDA first released concerns about the safety of transvaginal placement of mesh. From 2008 to 2010, the FDA received three to five times as many adverse reports associated with mesh used for pelvic organ prolapse repair than what agency received from 2005 to 2007 (nearly 1,000 reports of adverse events were received from 2005-2007).

Many of these patients complain because of erosion or contraction of the mesh material (which has been described as being of a similar material as Rubbermaid storage containers).  The erosion leads to bleeding, severe pelvic pain, painful (or impossible) sexual performance and a recurrence of urinary problems.

In July 2011, the Food and Drug Administration (FDA) issued an update related to what it called ‘serious complications’ related to the use of vaginal mesh for treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI).  It is now known that complications linked to transvaginal placement of surgical mesh in SUI and POP patients are not rare and can require multiple surgeries to correct problems related to the use of surgical mesh. In fact, the FDA now says that additional surgeries may actually not be able to repair damage caused by implantation of the mesh.

In other words, the side effects of the mesh placement may be permanent.  These complications from transvaginal placement of surgical mesh include:

• -Erosion of the implanted mesh
• -Infection and/or bleeding
• -Pain, including pain during sexual intercourse
• -Problems with organs near the implantation site

Helping You

You may have experienced mesh erosion, bleeding, urinary infections, vaginal scarring, pain during sexual intercourse, failure to conduct sexual intercourse and more. A physician may have tried to remove the mesh and been unable to do so. You may be in excruciating pain, and need help. We are offering free case evaluations to the general public across the United States and Canada. Manufacturers we consider include American Medical Systems, Bard, Boston Scientific, Ethicon,Gynecare, and Johnson & Johnson.

If you received a transvaginal mesh / sling and have been injured, you may be entitled to monetary compensation. Problems include pain, inability to have intercourse,bleeding, mesh growth into the body, mesh erosion, and more. Problems could be irreversible. Please fill out the form to the right or call us so that we can provide you with forms to evaluate your potential case immediately.

We are accepting case evaluations nationwide and in Canada, as well.  Please do not hesitate or delay in contacating TVM / TVT Sling and transvaginal mesh attorneys :

CALL: 1-800-632-1404

EMAIL: clicking here

FILL OUT THIS FORM FOR A FREE CONSULTATION AND CASE EVALUATION:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

• Comments